{"url_path":"/sec/cldx/8-k/2026-06-26/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/744218/0001104659-26-078023-index.html","accession_number":"0001104659-26-078023","cik":"0000744218","ticker":"CLDX","issuer_name":"Celldex Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/744218/0001104659-26-078023-index.html","primary_entity_key":"0000744218","primary_entity_name":"Celldex Therapeutics, Inc."},"word_count":298,"has_tables":true,"body_markdown":"false\n0000744218\n\n0000744218\n\n2026-06-25\n2026-06-25\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n** **\n\n**UNITED STATES**\n\n**SECURITIES AND\nEXCHANGE COMMISSION**\n\n**Washington, D.C.\n20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant\nto Section 13 or 15(****d)\nof the Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported):\n**June 25, 2026**\n\n \n\n**Celldex\nTherapeutics, Inc.**\n\n(Exact name of registrant as specified in its\ncharter)\n\n \n\n**Delaware**\n \n**000-15006**\n \n**13-3191702**\n\n(State\nor other jurisdiction of incorporation)\n \n(Commission\nFile Number)\n \n(IRS\nEmployer Identification No.)\n\n \n\n**Perryville III Building, 53 Frontage Road, Suite 220,**\n\n**Hampton****,\nNew Jersey****08827**\n\n(Address of principal executive offices) (Zip\nCode)\n\n \n\n**(908****)\n200-7500**\n\n(Registrant’s telephone number, including\narea code)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨\nWritten communications\npursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨\nSoliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨\nPre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨\nPre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant\nto Section 12(b) of the Act:\n\n \n\nTitle\nof each class\nTrading\nSymbol(s)\nName\nof each exchange on which registered\n\nCommon\nStock, par value $.001\nCLDX\nNasdaq\nCapital Market\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR\n§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).\n\n \n\nEmerging\ngrowth company ¨\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}